UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000055948 |
|---|---|
| Receipt number | R000063939 |
| Scientific Title | Network meta-analysis of chemoradiotherapy for limited-stage small cell lung cancer |
| Date of disclosure of the study information | 2024/10/25 |
| Last modified on | 2025/01/16 09:37:37 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Network meta-analysis of chemoradiotherapy for limited-stage small cell lung cancer
Acronym
Network meta-analysis of chemoradiotherapy for limited-stage small cell lung cancer
Scientific Title
Network meta-analysis of chemoradiotherapy for limited-stage small cell lung cancer
Scientific Title:Acronym
Network meta-analysis of chemoradiotherapy for limited-stage small cell lung cancer
Region
| Japan | North America | South America |
| Australia | Europe | Africa |
Condition
Condition
limited disease small cell lung cancer
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
This network meta-analysis evaluates the relative efficacy and safety of primary regimens in limited disease small cell lung cancer
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
OS
Key secondary outcomes
PFS, adverse events
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Limited disease small cell lung cancer,
chemotherapy therapy,
RCT
Key exclusion criteria
Extensive disease,
Not RCT
data insufficient
Target sample size
Research contact person
Name of lead principal investigator
| 1st name | Miao |
| Middle name | |
| Last name | Tang |
Organization
Medical Research Institute Tokyo Medical and Dental University
Division name
Medical Research Institute Tokyo Medical and Dental University
Zip code
113-8510
Address
1-5-45 Yushima, Bunkyo-ku, Tokyo
TEL
03-3813-6111
mtang69@live.cn
Public contact
Name of contact person
| 1st name | Miao |
| Middle name | |
| Last name | Tang |
Organization
Medical Research Institute Tokyo Medical and Dental University
Division name
Medical Research Institute Tokyo Medical and Dental University
Zip code
113-8510
Address
1-5-45 Yushima, Bunkyo-ku, Tokyo
TEL
03-3813-6111
Homepage URL
mtang69@live.cn
Sponsor or person
Institute
Medical Research Institute Tokyo Medical and Dental University
Institute
Department
Personal name
Funding Source
Organization
Medical Research Institute Tokyo Medical and Dental University
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Medical Research Institute Tokyo Medical and Dental University
Address
1-5-45 Yushima, Bunkyo-ku, Tokyo
Tel
03-3813-6111
mtang69@live.cn
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2024 | Year | 10 | Month | 25 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
889
Results
Etoposide-Platinum with Durvalumab demonstrated survival benefits and a favorable safety profile, positioning it as a promising option for LD-SCLC. Future studies should continue to explore ICI combinations to further optimize patient outcomes.
Results date posted
| 2025 | Year | 01 | Month | 16 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2024 | Year | 10 | Month | 10 | Day |
Date of IRB
| 2024 | Year | 10 | Month | 24 | Day |
Anticipated trial start date
| 2024 | Year | 10 | Month | 24 | Day |
Last follow-up date
| 2024 | Year | 11 | Month | 15 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Not available
Management information
Registered date
| 2024 | Year | 10 | Month | 25 | Day |
Last modified on
| 2025 | Year | 01 | Month | 16 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000063939
